跳至主要内容
临床试验/KCT0003788
KCT0003788已完成未知

Efficacy and safety of SGE on menopausal symptoms; A 12week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial

Bioland0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
40(Year) 至 60(Year)(—)
性别
Female

入选标准

  • 1) 40 to 60 year-old women who have passed one year since the last menstrual period or who have FSH 30 mIU/ml without uterus
  • 2) Kupperman Index score of 20 of more

排除标准

  • 1) BMI(Body Mass Index) > 30Kg/m2
  • 2) Hormone therapy within the past 3 months
  • 3) Subject with severe mental illness, such as depression and anxiety disorder, or who is currently taking neuro-psychotic drugs such as antidepressants
  • 4) When a clinically significant abnormality (BI-RADS(Breast Imaging Reporting and Data System) Category 0 or 3 or more, PAP smear(Papanicolaou smear) is normal up to ASCUS(Atypical Squamous Cell Undetermined Significance)) is confirmed from Mammography/PAP smear
  • 5) Subject who is taking osteoporosis drugs such as Bisphosphonate

研究者

发起方
Bioland

相似试验